CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,420,843 | +61.6% | 31,303 | +99.9% | 0.00% | 0.0% |
| Q2 2023 | $879,321 | +39.5% | 15,663 | +12.4% | 0.00% | 0.0% |
| Q1 2023 | $630,144 | -25.9% | 13,932 | -33.4% | 0.00% | 0.0% |
| Q4 2022 | $849,829 | -38.5% | 20,906 | -4.9% | 0.00% | 0.0% |
| Q1 2022 | $1,381,000 | -60.5% | 21,994 | -52.3% | 0.00% | -66.7% |
| Q4 2021 | $3,492,000 | -85.7% | 46,080 | -78.9% | 0.00% | -88.5% |
| Q3 2021 | $24,495,000 | +1086.2% | 218,844 | +1616.0% | 0.03% | +766.7% |
| Q2 2021 | $2,065,000 | -17.0% | 12,753 | -37.5% | 0.00% | -25.0% |
| Q1 2021 | $2,488,000 | – | 20,420 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |